First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.

  Health   Dec 11, 2023   0   60  Add to Reading List
First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

ARE YOU TIRED OF LOW SALES TODAY?

Connect to more customers on doacWeb

Post your business here..... from NGN1,000

WhatsApp: 09031633831

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow